- Home
- ACRS vs CADL Comparison
ACRS vs CADL Comparison
Compare ACRS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | CADL |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 280.3M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACRS | CADL |
|---|---|---|
| Price | $3.06 | $4.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $9.75 | ★ $18.50 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 05-27-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,683,000.00 | $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $4.25 |
| 52 Week High | $4.89 | $9.08 |
Technical Indicators
Market Signals| Indicator | ACRS | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 39.29 |
| Support Level | $2.78 | $4.44 |
| Resistance Level | $3.46 | $6.16 |
| Average True Range (ATR) | 0.21 | 0.27 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 44.53 | 20.37 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.